Nexstim, a Finland-based developer of non-invasive brain diagnostic and therapy technologies, has extended its latest round by €2m ($3m) after backing from a European financial investor.

Capricorn Health-tech Fund provided the money as a new investor and took the round total to €13.4m.

It joined a consortium including Lundbeckfond Ventures, the quasi-corporate venturing unit of Denmark-based Lundbeck Foundation, pension fund Ilmarinen, venture capital firms HealthCap and LSP (Life Sciences Partners), and state-backed Sitra, which is the Finnish Innovation Fund, and the Finnish Industry Investment.

Since launch in 2000, Nexstim has raised more than €30m. Lundbeckfond Ventures joined the consortium in January, when Casper Breum, investment director at the unit who also joined Nexstim’s board, said: "Now that Nexstim has proven the clinical value of its technology in neurosurgery, we are excited to be able to help the company realize its potential to become a significant player in the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?